Welcome to our dedicated page for Pharmather Holdings news (Ticker: PHRRF), a resource for investors and traders seeking the latest updates and insights on Pharmather Holdings stock.
PharmaTher Holdings Ltd. develops specialty pharmaceutical platforms centered on microneedle drug delivery. Company updates focus on PharmaPatch™ product programs for ketamine, psychedelics, GLP-1 drugs and therapeutic peptides, along with PatchPrint™, its automated tabletop microneedle patch 3D printer designed to support end-to-end patch manufacturing.
Recurring news themes include U.S. patent applications for patch manufacturing and peptide formulations, expansion of the PharmaPatch™ platform into new drug categories, regulatory and policy developments affecting ketamine, psychedelics and peptides, and the company's retained economic participation tied to its previously approved and sold U.S. generic ketamine ANDA.
Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF) has announced that their shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC) in the U.S. This development is expected to enhance accessibility and visibility for U.S. investors, potentially increasing liquidity and expanding the shareholder base. CEO Fabio Chianelli noted the company is focused on developing psychedelic pharmaceuticals for neuropsychiatric and neurological diseases, including novel delivery methods for substances like ketamine and psilocybin.
PharmaTher Inc., a subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), has partnered with the Terasaki Institute to develop a microneedle patch for delivering psychedelic pharmaceuticals like psilocybin and MDMA. This innovative technology utilizes biodegradable GelMA material, aiming to address issues with oral and injection methods. PharmaTher's goal is to gain FDA approval for treatments targeting mental health and neurological disorders through this delivery system, enhancing patient compliance and treatment outcomes.
PharmaTher Inc. (CSE: PHRM, OTCQB: PHRRF) has reported a successful Type B pre-IND meeting with the FDA regarding its clinical development plan for ketamine to treat levodopa-induced dyskinesia in Parkinson’s disease patients. The FDA confirmed the acceptability of a 505(b)(2) regulatory pathway, potentially expediting drug approval. The proposed Phase 2 study has received FDA support for its primary efficacy endpoint and safety parameters. PharmaTher plans to file an IND application in Q1-2021, aiming to initiate the Phase 2 study in Q2-2021.
PharmaTher Inc., a subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), has entered into an exclusive worldwide license agreement with The Queen’s University of Belfast for a patented microneedle delivery technology. This partnership will support the development of the KETABET™ microneedle patch, combining ketamine and betaine for treating mental health and neurological disorders. The patch aims to provide a non-invasive delivery method that enhances patient compliance and reduces side effects associated with ketamine treatment.